<DOC>
	<DOCNO>NCT02661451</DOCNO>
	<brief_summary>The objective study determine safety efficacy transcatheter aortic valve replacement ( TAVR ) via transfemoral approach HF patient moderate AS compare OHFT .</brief_summary>
	<brief_title>Transcatheter Aortic Valve Replacement UNload Left Ventricle Patients With ADvanced Heart Failure ( TAVR UNLOAD )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . NYHA class ≥ 2 2 . NTproBNP &gt; 1500 pg/mL ( BNP &gt; 400 pg/mL ) hospitalization HF within last year 3 . Under appropriate guidelinedirected HF therapy ( include cardiac resynchronization therapy ) minimum 3 month . 4 . Moderate AS define ( must meet ) : Mean transaortic gradient ( MG ) ≥ 20 mmHg &lt; 40 mmHg rest dobutaminestress echocardiography ( DSE ) Aortic valve area ( AVA ) &gt; 1.0 cm2 DSE Aortic valve area ( AVA ) ≤1.5 cm2 rest 5 . Left ventricular ( LV ) ejection fraction ( EF ) &lt; 50 % 6 . Anatomically suitable transfemoral TAVR SAPIEN 3 THV 1 . LVEF &lt; 20 % persistent need intravenous inotropic support 2 . Hospitalization acute decompensated HF within 2 week prior randomization 3 . Cardiac resynchronization therapy device implantation within 3 month prior randomization 4 . Coronary artery revascularization ( PCI CABG ) within 3 month prior randomization 5 . In need suitable revascularization per heart team consensus 6 . Severe aortic regurgitation 7 . Congenital unicuspid congenital bicuspid aortic valve 8 . Concomitant nonaortic valvular disease formal indication valve surgery per establish guideline ( ESC/ACC/AHA ) 9 . Previous aortic valve replacement ( mechanical bioprosthetic ) 10 . Severe mitral regurgitation due degenerative mitral disease ( primary MR ) 11 . Previous stroke permanent disability ( modify Rankin score ≥ 2 ) 12 . Chronic obstructive pulmonary disease GOLD 4 13 . Severe chronic kidney disease : glomerular filtration rate &lt; 30 mL/min MDRD need renal replacement therapy 14 . Gastrointestinal bleeding within past 3 month 15 . Liver cirrhosis ChildPugh C 16 . Active systemic infection , include active endocarditis 17 . Unwilling accept blood transfusion 18 . Evidence intracardiac mass , thrombus , vegetation 19 . Absence minimum amount aortic valve calcification necessary TAVR SAPIEN 3 THV 20 . Hypersensitivity contraindication clopidogrel , aspirin , oral anticoagulation indicate ( eg , subject atrial fibrillation ) . 21 . Sensitivity contrast medium adequately premedicated 22 . Women childbearing potential 23 . Clinical sign dementia 24 . Other medical , social , psychological condition precludes appropriate consent followup 25 . Life expectancy &lt; 2 year due cancer noncardiac chronic diseases 26 . Unwillingness undergo followup investigation 27 . Currently participate investigational drug another device trial reach primary endpoint ( exclude registry ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Valve</keyword>
</DOC>